Surveillance Workgroup (SRV-WG) Q4-2015 Update
The SRV-WG is defining the magnitude and trends of drug resistance in high burden countries, with particular focus on new and existing drugs for which resistance surveillance data are largely unavailable. Furthermore, the SRV-WG will explore the development of novel strategies for surveillance of TB drug resistance based on high-throughput molecular technologies.
- Facilitate the production of surveillance data on resistance to new and selected existing drugs.
- Validate high-throughput molecular methods for surveillance of drug resistance.
- Develop a glossary of terms and standardized language for drug-resistant surveillance.
- Lead the development of a TB drug sequencing data platform.
4Q, 2015 Progress:
- The WHO presented results from the first phase of its geno/pheno project for PZA and FQ with five representative countries (Azerbaijan, Belarus, Pakistan, Bangladesh and South Africa) at an October meeting in Geneva. Results include:
- A high correlation between phenotypic profiles and PZA sequencing.
- FQ produced several discordant results. The WHO is considering lowering the critical concentration of moxifloxacin. A lower critical concentration may result in better correlation between the two methods (Sequencing vs MGIT). One caveat is that FQ resistance was rare in the study.
- The WHO is preparing a manuscript which it expects to submit in Q1, 2016.
- The WHO Is correlating geno/pheno profiles of Rifampin and Isoniazid. The collection of whole genome sequencing data in the initial five countries (listed in previous bullet), the Ukraine, and the Philippines is more than half complete.
- Standardized Reporting Language Workshop planning:
- The SRV-WG finalized the workshop agenda which will focus on understanding the challenges with standardized reporting language and identify a globally useful nomenclature.
- Participants from five disciplines (epidemiology, clinical, laboratory, public health and industry) have confirmed attendance.
- Finalized meeting logistics.